
    
      This clinical trial is a early phase 1, open label, single center, single arm study of the
      combination of intravenously administered SGT-53 and irradiation and/or chemotherapy in
      pediatric patients with recurrent or progressive CNS malignancies. The objective of the study
      is to establish the safety and feasibility of administration of SGT-53 in conjunction with
      conventional radiotherapy and/or chemotherapy in children with recurrent or refractory CNS
      malignancies.
    
  